top of page
Executive Spotlights

GSK Strengthens mRNA Capabilities with Strategic $1.56B Acquisition of CureVac’s Vaccine Portfolio

London, July 3, 2024 (Reuters) -- In a strategic move to enhance its mRNA technology portfolio, British pharmaceutical giant GSK has acquired full rights to CureVac's experimental vaccines targeting COVID-19 and influenza. This acquisition, begins with a $435 Million upfront payment and provides a critical financial lifeline to CureVac.

Read full article here.

Recent Posts

See All

Radiant Vision Systems Appoints new CEO

Redmond, WA, July 1, 2024 (Radiant) -- Radiant Vision Systems has appointed Stone Jiang as their new CEO, succeeding Doug Kreysar who is retiring. Jiang, previously the Executive Vice President and

Orion and Merck Secure $1.63B Agreement

Rahway, NJ, July 1, 2024 (Business Wire) -- Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, and Orion Corporation ("Orion") have agreed to convert their co-development and co-commercial


Life Science Headlines
bottom of page